The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Diabetic atherosclerosis in APOE*4 mice: synergy between lipoprotein metabolism and vascular inflammation
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In mice, the development of atherosclerosis is accelerated when human LDLR and E4 are combined in the background of diabetes.
“In addition, the development of atherosclerosis is accelerated in mice when human LDLR and E4 were combined in the background of diabetes (Johnson et al., 2013).”
From Apolipoprotein E–low density lipoprotein receptor interaction affects spatial memory retention and brain ApoE levels in an isoform-dependent manner (2014) · cites this paper as Johnson et al., 2013
Increasing LDLR expression in the presence of apoE4 has harmful effects in a mouse model of CVD.
“Given the harmful effects of increasing LDLR expression in the presence of apoE4 in a mouse model of CVD (Altenburg et al., 2007, Johnson et al., 2013, Malloy et al., 2004)”
From Apolipoprotein E–low density lipoprotein receptor interaction affects spatial memory retention and brain ApoE levels in an isoform-dependent manner (2014) · cites this paper as Johnson et al., 2013
In mice, introduction of human LDLR results in higher plasma cholesterol and increased cardiovascular complications in the presence of E4.
“In mice, introduction of human LDLR results in higher plasma cholesterol and increased cardiovascular complications in the presence of E4 (Altenburg et al., 2007, Malloy et al., 2004, Johnson et al., 2013).”
From Apolipoprotein E–low density lipoprotein receptor interaction affects spatial memory retention and brain ApoE levels in an isoform-dependent manner (2014) · cites this paper as Johnson et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sullivan, P. M., Mezdour, H., Aratani, Y., Knouff, C., Najib, J., Reddick, R. L., Quarfordt, S. H., & Maeda, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.29.17972 · Cited by 575
Self-citationDiet-induced hypercholesterolemia in mice: prevention by overexpression of LDL receptors
Yokode, M., Hammer, R. E., Ishibashi, S., Brown, M. S., & Goldstein, J. L. (1990) · Science · doi:10.1126/science.2244210 · Cited by 175
FoxO1 integrates insulin signaling to VLDL production.
Kamagate, A., & Dong, H. H. (2008) · Cell Cycle · doi:10.4161/cc.7.20.6882 · Cited by 127
Hara, M., Matsushima, T., Satoh, H., Iso-o, N., Noto, H., Togo, M., Kimura, S., Hashimoto, Y., & Tsukamoto, K. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054199.78458.4b · Cited by 53
Flagged first, then by citations
Research works printed but not linked: 38
- Kannel, 1979, Diabetes and cardiovascular disease: the Framingham Study, JAMA., 241, 2035, 10.1001/jama.1979.03290450033020 · DOI · Paper page
- Grundy, 1999, Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association, Circulation., 100, 1134, 10.1161/01.CIR.100.10.1134 · DOI · Paper page
- Goldberg, 2001, Clinical review 124: Diabetic dyslipidemia: causes and consequences, J. Clin. Endocrinol. Metab., 86, 965, 10.1210/jcem.86.3.7304 · DOI
- Jenkins, 2003, Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia, Diabetes Care., 26, 810, 10.2337/diacare.26.3.810 · DOI
- Johnson, 2010, Macrovascular complications of diabetes in atherosclerosis prone mice, Expert Rev. Endocrin. & Metab., 5, 89, 10.1586/eem.09.66 · DOI
- Hsueh, 2007, Recipes for creating animal models of diabetic cardiovascular disease, Circ. Res., 100, 1415, 10.1161/01.RES.0000266449.37396.1f · DOI
- Renard, 2004, Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions, J. Clin. Invest., 114, 659, 10.1172/JCI200417867 · DOI
- Wang, 1999, A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse, J. Clin. Invest., 103, 27, 10.1172/JCI4431 · DOI
- Zhou, 2011, Hyperglycemic Ins2AkitaLdlr−/− mice show severely elevated lipid levels and increased therosclerosis: a model of type 1 diabetic macrovascular disease, J. Lipid Res., 52, 1483, 10.1194/jlr.M014092 · DOI
- Mahley, 2000, Apolipoprotein E: far more than a lipid transport protein, Annu. Rev. Genomics Hum. Genet., 1, 507, 10.1146/annurev.genom.1.1.507 · DOI · Paper page
- Knouff, 1999, Apo E structure determines VLDL clearance and atherosclerosis risk in mice, J. Clin. Invest., 103, 1579, 10.1172/JCI6172 · DOI · Paper page
- Malloy, 2004, Harmful effects of increased LDLR expression in mice with human APOE*4 but not APOE*3, Arterioscler. Thromb. Vasc. Biol., 24, 91, 10.1161/01.ATV.0000094963.07902.FB · DOI · Paper page
- Jun, 2011, Spontaneously diabetic Ins2+/Akita:apoE-deficient mice exhibit exaggerated hypercholesterolemia and atherosclerosis, Am. J. Physiol. Endocrinol. Metab., 301, E145, 10.1152/ajpendo.00034.2011 · DOI
- Knouff, 2001, Doubling expression of the low density lipoprotein receptor by truncation of the 3′-untranslated region sequence ameliorates type iii hyperlipoproteinemia in mice expressing the human apoe2 isoform, J. Biol. Chem., 276, 3856, 10.1074/jbc.M009423200 · DOI · Paper page
- Johnson, 2008, Absence of hyperlipidemia in LDL receptor-deficient mice having apolipoprotein B100 without the putative receptor-binding sequences, Arterioscler. Thromb. Vasc. Biol., 28, 1745, 10.1161/ATVBAHA.108.169680 · DOI
- de Silva, 1994, Identification of apolipoprotein B-100 low density lipoproteins, apolipoprotein B-48 remnants, and apolipoprotein E-rich high density lipoproteins in the mouse, J. Lipid Res., 35, 1297, 10.1016/S0022-2275(20)39973-9 · DOI
- Altenburg, 2007, Apolipoprotein E4 in macrophages enhances atherogenesis in a low density lipoprotein receptor-dependent manner, J. Biol. Chem., 282, 7817, 10.1074/jbc.M610712200 · DOI · Paper page
- Sparks, 1994, Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion, Biochim. Biophys. Acta., 1215, 9, 10.1016/0005-2760(94)90088-4 · DOI
- Twisk, 2000, The role of the LDL receptor in apolipoprotein B secretion, J. Clin. Invest., 105, 521, 10.1172/JCI8623 · DOI
- Hirota, 1993, Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification, Am. J. Pathol., 143, 1003
- Matsumoto, 1998, Expression and localization of matrix metalloproteinase-12 in the aorta of cholesterol-fed rabbits: relationship to lesion development, Am. J. Pathol., 153, 109, 10.1016/S0002-9440(10)65551-4 · DOI
- Altenburg, 2008, Human LDL receptor enhances sequestration of ApoE4 and VLDL remnants on the surface of hepatocytes but not their internalization in mice, Arterioscler. Thromb. Vasc. Biol., 28, 1104, 10.1161/ATVBAHA.108.164863 · DOI
- Stalenhoef, 1984, Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in normal and lipoprotein lipase-deficient humans, Proc. Natl. Acad. Sci. USA., 81, 1839, 10.1073/pnas.81.6.1839 · DOI
- Cannon, 2007, High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome, Clin. Cornerstone., 8, S14, 10.1016/S1098-3597(07)80011-1 · DOI
- Goldberg, 2004, Effects of streptozotocin-induced diabetes in apolipoprotein AI deficient mice, Atherosclerosis., 172, 47, 10.1016/j.atherosclerosis.2003.09.014 · DOI
- Kako, 2002, Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice, J. Lipid Res., 43, 872, 10.1016/S0022-2275(20)30460-0 · DOI
- Fonseca, 2004, Nontraditional risk factors for cardiovascular disease in diabetes, Endocr. Rev., 25, 153, 10.1210/er.2002-0034 · DOI
- Chait, 2009, Diabetes and atherosclerosis: is there a role for hyperglycemia?, J. Lipid Res., 50, S335, 10.1194/jlr.R800059-JLR200 · DOI
- Funk, 2012, Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes, Int. J. Vasc. Med., 2012, 569654
- Dansky, 2001, Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage, Arterioscler. Thromb. Vasc. Biol., 21, 1662, 10.1161/hq1001.096625 · DOI
- Cybulsky, 2001, A major role for VCAM-1, but not ICAM-1, in early atherosclerosis, J. Clin. Invest., 107, 1255, 10.1172/JCI11871 · DOI
- Tang, 2010, Diabetes reduces the cholesterol exporter ABCA1 in mouse macrophages and kidneys, J. Lipid Res., 51, 1719, 10.1194/jlr.M003525 · DOI
- Parathath, 2011, Diabetes adversely affects macrophages during atherosclerotic plaque regression in mice, Diabetes., 60, 1759, 10.2337/db10-0778 · DOI
- Lucic, 2007, Regulation of macrophage apoE secretion and sterol efflux by the LDL receptor, J. Lipid Res., 48, 366, 10.1194/jlr.M600259-JLR200 · DOI
- Cullen, 1998, Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages, J. Clin. Invest., 101, 1670, 10.1172/JCI119887 · DOI
- Cash, 2012, Apolipoprotein E4 impairs macrophage efferocytosis and potentiates apoptosis by accelerating endoplasmic reticulum stress, J. Biol. Chem., 287, 27876, 10.1074/jbc.M112.377549 · DOI
- Nakamuta, 1995, Alternative mRNA splicing and differential promoter utilization determine tissue-specific expression of the apolipoprotein B mRNA-editing protein (Apobec1) gene in mice. Structure and evolution of Apobec1 and related nucleoside/nucleotide deaminases, J. Biol. Chem., 270, 13042, 10.1074/jbc.270.22.13042 · DOI
- Versmissen, 2011, Apolipoprotein isoform E4 does not increase coronary heart disease risk in carriers of low-density lipoprotein receptor mutations, Circ. Cardiovasc. Genet., 4, 655, 10.1161/CIRCGENETICS.111.959858 · DOI
Cited by
Sorted by citations
Johnson, L. A., Olsen, R. H. J., Merkens, L. S., DeBarber, A., Steiner, R. D., Sullivan, P. M., Maeda, N., & Raber, J. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.12.016 · Cited by 107
Self-citationKou, J., Wang, M., Shi, J., Zhang, H., Pu, X., Song, S., Yang, C., Yan, Y., Döring, Y., Xie, X., et al. (2021) · ACS Omega · doi:10.1021/acsomega.0c04810 · Cited by 52
Metadata
- Authors
- Johnson, L. A., Kim, H.-S., Knudson, M. J., Nipp, C. T., Yi, X., & Maeda, N.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2013-02
- Volume
- 54
- Issue
- 2
- Pages
- 386-396
- ISSN
- 0022-2275
- Cited by
- 13
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
